Mumbai: Shares of Surat-based Sahajanand Medical Technologies Limited, the Company has built a strong clinical foundation for its flagship products – Supraflex Cruz, Hydra, Sironity Drug-coated PTCA Balloon, Pipit and Cocoon, supported by 75 clinical studies (comprising 66 completed studies and 09 ongoing studies), as of June 30, 2026, across diverse geographies and patient populations was listed at Rs 368.05 on the BSE with a premium of 7% to the IPO price.

The scrip reached a high of Rs 409.95 on the NSE, and Rs 409.95 on the BSE.

The scrip closed at Rs 377.65 on the NSE and Rs 375 on BSE.

As per NSE, the total quantity traded stood at 13.02 lakh shares, on BSE the total Quantity stood at 174 lakh shares. Total Turnover (BSE+NSE) on Day 1 stood at Rs 709.55 crore.

The Market Capitalisation of the Company at today’s closing price stood at Rs 3,844.28 crore as per BSE and Rs. 3,838.69 crore as per NSE.

The issue received bids of 13,84,72,771 equity shares against the offered 97,50,482 equity shares, according to data available on the stock exchanges.

Qualified Institutional Buyers (QIB) and Retail Portion were subscribed 34.70 times and 3.03 times, respectively. Non-Institutional Investors (NII) portion was subscribed 14.64 times whereas the employee reserved portion subscribed 0.37 times.